Close Menu

NEW YORK – Personalis reported after the close of the market on Thursday that its fourth quarter revenues were up 11 percent year over year, driven by growth in its pharmaceutical services business and other non-VA customers.

For the three months ended Dec. 31, 2020, the cancer genomics company reported revenues of $20.2 million, up from $18.2 million in the same quarter in 2019 and edging the average Wall Street estimate of $20.1 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

Nature News writes that viral genomic surveillance in the US faces systemic issues.

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.

Apr
21
Sponsored by
Mission Bio

This webinar, the first in a “Meet the Authors” series sponsored by Mission Bio, will discuss the application of single-cell analysis to decipher clonal evolution across several stages of disease development in myeloid malignancies. 

Apr
22
Sponsored by
10x Genomics

The human immune system is extremely complex, comprised of multiple cell types and states interacting in myriad ways to produce diverse cellular ecosystems.

Apr
23
Sponsored by
Isoplexis

Recent advances in single-cell technologies have provided unprecedented -omic-level insights into cellular heterogeneity and function. 

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.